ROBIN CASSIDY: Open Payments
NPI 1215968789 · APEX, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,271 in 58 payments from 14 companies in 2025. Trend: 2023 $993 · 2024 $939 · 2025 $1,271
Food & beverage: $1,271
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 10 | $262 |
| ABBVIE INC. | 10 | $229 |
| Lundbeck LLC | 9 | $166 |
| Vanda Pharmaceuticals Inc. | 7 | $148 |
| Neurocrine BioSciences, Inc. | 4 | $99 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $84 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| E.R. Squibb & Sons, L.L.C. | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Axsome Therapeutics, Inc. | 2 | $39 |
Products named: AUSTEDO XR, REXULTI, VRAYLAR, HETLIOZ, INGREZZA, CAPLYTA, COBENFY, TRINTELLIX.
Industry payments across NC — which companies pay providers there.
